Nektar therapeutics (NKTR)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10
Cash flows from operating activities:
Net loss

-138,651

-113,438

-98,808

-108,789

-119,632

-98,212

-96,143

971,460

-95,792

-33,826

60,871

-59,871

-63,866

-42,199

-43,224

-48,603

-19,498

-54,137

-8,203

-52,657

33,820

-45,683

70,605

-32,637

-46,201

-47,659

-16,543

-42,748

-55,063

-52,926

-43,547

-34,285

-41,097

-37,495

-24,068

-36,381

-36,034

-22,580

-8,711

-517

-6,130

Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to sale of future royalties

9,900

8,700

10,300

9,100

8,200

9,000

8,300

9,080

6,920

9,133

8,066

6,638

6,663

7,817

7,691

8,115

6,535

7,306

6,050

4,740

3,962

5,184

6,143

4,837

5,773

9,311

4,523

3,828

4,393

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to sale of future royalties

7,000

7,100

5,900

5,900

6,100

6,400

4,800

4,981

5,019

5,365

4,471

4,512

4,552

4,783

4,902

4,982

5,045

5,191

5,226

5,152

5,050

5,163

5,204

5,134

5,387

5,665

5,616

5,485

5,543

5,416

5,486

5,370

1,785

-

-

-

-

-

-

-

-

Stock-based compensation

25,236

25,008

24,880

24,522

25,385

24,206

23,287

20,659

19,949

11,497

8,835

8,099

8,184

7,057

6,166

6,264

6,363

5,170

4,762

4,560

5,177

4,370

4,122

4,164

4,361

4,543

4,564

4,356

4,245

4,184

3,980

3,801

4,234

4,384

4,819

4,880

4,802

4,683

4,611

4,361

3,744

Depreciation and amortization

4,502

3,574

3,450

3,055

3,077

3,071

2,684

2,574

2,541

2,660

3,794

4,254

4,033

3,849

3,868

3,919

3,715

3,746

3,276

2,860

2,973

3,194

3,214

3,255

3,264

3,393

3,601

3,653

3,628

3,698

3,858

3,442

3,510

3,527

3,775

3,793

3,856

4,052

4,165

4,185

4,149

Impairment of advance payments to contract manufacturers and equipment for terminated program

20,351

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of long-lived assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,675

-

-

-

-

-

-

-

-

Accretion of premiums (discounts), net and other non-cash transactions

1,289

973

2,595

4,643

3,183

2,816

4,145

3,621

370

-489

281

358

731

-5

930

643

617

917

827

-317

938

873

552

-88

-777

-332

-173

-20

-139

-1,879

47

-393

-295

-2,326

1,587

-311

-309

-374

381

30

-235

Changes in operating assets and liabilities:
Accounts receivable

5,229

-4,403

3,906

-5,595

-319

9,326

-3,378

19,708

-151

1,700

-800

2,549

-14,113

1,429

-13,528

-11,900

19,730

16,981

-714

795

-722

-42,467

43,027

1,192

-374

-2,328

-1,484

2,394

-2,158

1,894

-7,450

558

5,865

-32,352

28,830

6,300

-22,942

19,549

-3,893

1,737

2,908

Inventory

1,655

-1,055

532

1,410

397

-1,915

1,412

1,209

-51

-2,928

2,646

-2,008

1,907

355

492

-988

-96

994

228

-2,387

-441

1,257

-2,416

1,239

-580

-1,624

-5,403

2,098

112

1,515

2,039

607

1,452

8,778

-5,919

-1,915

4,446

-4,194

1,683

1,074

2,232

Operating leases, net

-2,940

-

-

-

-1,168

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-1,067

16,937

-2,309

-11,609

-4,209

9,565

7,805

16,135

-1,853

2,764

4,316

-146

-2,134

6,353

-1,404

-343

-4,294

4,668

-3,653

2,619

-2,809

3,973

59

-1,456

718

394

-1,309

-1,664

-3,844

4,562

-2,417

-3,871

-4,305

14,017

-3,941

992

1,199

-576

-137

-747

883

Accounts payable

2,687

-3,142

12,629

-1,676

5,156

-1,640

-3,180

-701

6,492

-3,655

2,508

-896

4,117

-4,281

4,782

51

-34

113

-515

-2,251

2,241

-2,689

-1,852

4,308

-6,126

5,502

-1,934

1,276

1,355

279

-481

1,370

-1,290

816

-1,051

-254

-2,895

2,519

-428

435

1,748

Accrued compensation

9,920

-11,634

3,391

1,339

8,434

-17,985

8,942

3,850

6,867

-10,825

4,742

2,883

-6,817

2,547

3,270

2,419

4,046

-6,807

1,981

1,468

3,607

-8,004

2,367

1,959

-4,827

344

2,823

2,135

179

-3,914

2,168

2,332

-4,620

1,047

2,325

1,755

-1,572

-1,300

2,644

2,204

-4,348

Accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

693

-

-539

4,410

-1,130

1,960

-656

-903

1,094

-5,225

3,867

410

1,961

-2,407

3,078

-342

1,354

Accrued clinical trial expenses

-

-

-

-

-

-

-

-

-

-

317

-760

-515

-

-2,524

2,874

2,376

-2,882

2,156

199

1,039

-1,935

-3,565

-518

-3,179

1,666

-1,696

-7,097

6,532

4,300

593

-119

773

-1,659

-220

183

1,505

-3,431

590

266

552

Other accrued expenses

7,716

-6,203

-5,489

14,734

774

1,344

11,186

4,591

10,826

2,306

2,583

590

1,798

-2,457

-445

655

2,176

-3,227

-910

48

1,811

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-2,510

-7,100

-2,750

-2,511

-4,204

-4,400

-4,682

-2,571

-3,678

-43,746

19,364

-13,506

9,619

-4,950

-4,961

-677

-7,027

-5,698

-7,398

-6,427

1,993

-6,144

-6,156

13,593

-5,957

2,515

-12,096

-5,528

2,710

-5,954

-4,505

-2,151

3,226

-5,196

-4,771

-4,994

-2,555

36,082

-27,987

-28,552

-26,568

Interest payable

-

-

-

-

-

-

-

-

-

-

-

54

-108

-

-

0

-54

1,031

-3,750

3,750

-3,750

-

-

-

-3,750

3,750

-3,750

3,750

-3,916

-

-

-

-1,747

-

-

-

-

-

-

-

-

Other liabilities

-233

-11,399

3,231

8,537

164

-1,559

36

4,523

545

-15,974

46

3,509

-2,509

14,415

-5,068

-2,461

1,736

-822

-7,918

1,493

10,279

-6,435

-809

-5,362

-1,195

13,989

-3,602

2,607

-3,830

3,494

50

-825

556

1,738

-2,023

886

-1,544

1,802

-1,320

573

-1,302

Net cash used in operating activities

-78,075

-125,223

-68,641

-53,922

-80,895

-117,550

-71,412

959,642

-52,466

-80,401

93,076

-58,523

-34,566

-52,411

-27,361

-13,604

-23,648

-75,109

-14,031

-47,255

63,312

-24,627

-46,004

-9,085

-62,290

53,631

-19,710

-34,337

-38,111

-47,376

-27,171

-20,591

-34,618

-42,214

-21,870

-34,788

-14,870

20,407

-22,162

-19,953

-34,163

Cash flows from investing activities:
Purchases of investments

241,068

351,982

425,181

234,963

368,739

-

-

-

-

89,986

193,304

45,278

75,857

191,687

70,166

41,354

31,452

94,738

78,402

100,036

24,432

97,091

33,664

55,835

110,661

127,499

31,169

53,064

56,336

38,053

6,199

18,387

102,023

67,842

117,848

136,958

372,723

127,962

96,885

102,998

115,277

Maturities of investments

439,735

491,134

488,757

271,896

362,249

423,299

334,879

95,547

37,232

86,631

113,554

89,505

58,053

52,233

94,086

37,986

69,377

71,240

44,682

37,567

73,434

76,169

53,049

61,805

56,972

45,170

73,534

100,139

100,338

105,119

23,002

27,802

151,964

92,242

133,848

43,727

113,235

114,907

119,650

129,182

112,074

Sales of investments

-

-

-

-

-

0

0

37

11,963

28,677

0

0

8,823

0

4,969

0

0

18,766

18,563

0

5,215

-

-

-

-

-

-

-

-

-

-

-

-

-8,571

38,182

119,110

61,368

5,189

2,093

0

8,197

Purchases of property, plant and equipment

900

3,671

5,323

11,643

5,648

8,687

1,822

2,745

985

2,393

939

2,255

4,089

2,651

507

1,555

1,679

2,473

4,138

3,525

1,059

3,886

898

668

4,524

2,709

588

478

316

4,839

2,572

1,656

1,516

1,428

1,449

3,080

3,765

9,297

13,364

4,823

3,973

Net cash provided by (used in) investing activities

197,767

135,481

58,253

25,290

-12,138

87,540

-621,271

-894,415

48,210

22,978

-80,689

41,972

-13,070

-142,105

28,382

-4,923

36,246

-7,205

5,705

-65,994

53,158

-24,808

40,148

5,302

-58,213

-82,151

41,777

46,597

43,686

62,227

-5,391

7,759

48,425

14,401

52,733

22,799

-201,885

-17,163

11,494

21,361

1,021

Cash flows from financing activities:
Issuance of common stock to Bristol-Myers Squibb (Note 10)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-65

-18

116,619

-

-

-

-

-

-

-

-

-4,289

523

1,591

221,958

-

994

1,372

4,776

Repayment of proceeds from sale of future royalties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-7,000

0

0

0

-3,000

-

-

-

-

-

-

-

-

-

-

-

-

(Repayment of) proceeds from sale of future royalties, net of $4.4 million of transaction costs in 2012

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

119,589

-

-

-

-

-

-

-

-

Proceeds from shares issued under equity compensation plans

11,077

4,906

6,249

7,306

4,894

2,668

3,859

20,856

34,352

27,247

10,259

10,224

11,792

2,246

8,398

3,547

6,096

16,692

7,718

6,113

1,685

30,816

8,207

2,887

5,074

2,955

2,632

1,403

1,218

940

1,840

858

479

-

-

-

-

-

-

-

-

Payment of capital lease obligations

-

-

-

-

-

-

-

-

-

2,972

790

756

613

569

1,859

1,794

1,723

1,389

1,314

1,386

1,098

958

928

825

825

791

735

774

692

664

622

585

566

547

497

475

459

237

388

372

359

Net cash provided by financing activities

11,077

4,906

6,249

7,306

4,894

2,668

3,859

811,087

34,352

24,275

9,469

9,468

11,179

190,953

6,539

1,753

4,373

119,065

6,404

4,727

587

29,858

7,214

2,044

113,868

2,164

1,897

629

-2,474

210

-93,184

273

119,502

-306

26

1,116

221,499

1,512

606

1,000

4,417

Effect of foreign exchange rates on cash and cash equivalents

-97

-25

-61

-2

-14

-14

-40

6

-53

-57

-38

-248

297

-92

59

-99

8

0

-134

-55

30

-66

-49

-5

11

12

15

12

-7

38

-70

228

-136

-

-

-

-14

93

-276

264

-300

Net increase (decrease) in cash and cash equivalents

130,672

15,139

-4,200

-21,328

-88,153

-27,356

-688,864

876,320

30,043

-33,205

21,818

-7,331

-36,160

-3,655

7,619

-16,873

16,979

36,751

-2,056

-108,577

117,087

-19,643

1,309

-1,744

-6,624

-26,344

23,979

12,901

3,094

15,099

-125,816

-12,331

133,173

-27,696

31,382

-10,859

4,730

4,849

-10,338

2,672

-29,025

Supplemental disclosures of cash flow information:
Cash paid for interest

4,951

4,970

4,774

4,650

4,805

4,770

4,906

4,843

4,952

5,127

4,979

4,943

5,067

5,076

5,065

5,204

5,244

4,130

7,775

465

7,855

958

7,865

661

7,961

493

8,027

820

8,250

610

3,831

980

4,199

-

-

-

-

-

-

-

-

Operating lease right-of-use asset recognized in exchange for lease liabilities

2,133

-

-

-

1,289

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-